Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type Abstract
Authors A. Rose O. Ayodele S. Genta T. Pimentel Muniz D.C. Kelly K. Hodgson I. King T. Stockley T. Pugh Z. Saeed Kamil M.O. Butler F.A. Shepherd P. Bedard N. Leighl A.R. Abdul Razak A.R. Hansen S. Saibil D.W. Cescon L.L. Siu A. Spreafico
Title Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
Journal Annals of Oncology
Vol 32
Date September 01, 2021
Abstract Text Background Recurring oncogenic non-V600E BRAF mts can be identified in many cancers. Preclinical data indicate that they can be targeted with BRAF + MEK inhibitors. BEAVER is an investigator-initiated study designed to test the safety and efficacy of binimetinib and encorafenib (B+E) in patients (pts) with non-V600E BRAF mts. Methods Key eligibility criteria are: pts with advanced solid tumors with BRAF non-V600E activating (class 1 and 2) or inhibitory (class 3) mts, and no prior BRAF/MEKi. Pts receive binimetinib (45mg PO BID) and encorafenib (450mg PO daily) on a 28-day cycle until intolerable toxicity or progression. The primary objective is objective response rate (ORR) per RECIST 1.1. In this Simon 2-stage trial, ≥1 of 7 pts must have a response before commencing stage 2 (26 pts total). Secondary objectives include: safety, DCR, and PFS. Results From Jun 2019 to Apr 2021, 10 pts were enrolled; 10 are evaluable for safety and 9 for efficacy. Tumor types were: melanoma and colon (n=2 each), gallbladder, lung, breast, ampullary, pancreatic and uterine (n=1 each). Median age was 61 yrs (range 40-72). 1 pt had a class 1, 4 pts had class 2, and 5 pts had class 3, non-V600E BRAF mts. Common treatment-related adverse events were mostly Grade ≤ 2, and included: Blurred vision (70%), fatigue (60%) and nausea (50%). Dose reductions were required in 5/10 pts (50%) due to: blurred vision (20%), central serous retinopathy, malaise, increased lipase and nausea (10% each). Eye toxicities were reversible with dose interruption or reduction. Drug-related Grade 3 AEs occurred in 2/10 pts and included: malaise, confusion, fatigue and increased lipase (10% each). ORR was 22% (2/9) with a confirmed PR in a pt with ampullary cancer (BRAF D594G, class 3) who continues on treatment for 5.4+ months, and an unconfirmed PR in a melanoma pt (BRAF G469S, class 2) treated for 6.5 months. One gallbladder cancer pt (BRAF D594N, class 3) had SD, treated for 4.4 months, and 6 pts had PD as best response. Conclusions Preliminary data confirmed the safety of B+E and demonstrated evidence of anti-tumor activity in advanced cancer pts with non-V600E BRAF mts. Enrolment in the BEAVER trial is ongoing. Clinical trial identification NCT03839342.


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF G469S gallbladder cancer predicted - sensitive Binimetinib + Encorafenib Phase II Actionable In a Phase II trial (BEAVER), combination treatment with Mektovi (binimetinib) and Braftovi (encorafenib) led to stable disease in a gallbladder cancer patient harboring BRAF D594N, with a treatment duration of 4.4 months (Annals of Oncology 32 (2021): S596; NCT03839342). detail...
BRAF D594G ampulla of Vater cancer predicted - sensitive Binimetinib + Encorafenib Phase II Actionable In a Phase II trial (BEAVER), combination treatment with Mektovi (binimetinib) and Braftovi (encorafenib) led to a confirmed partial response in an ampullary cancer patient harboring BRAF D594G, who continued to be on treatment for 5.4 months (Annals of Oncology 32 (2021): S596; NCT03839342). detail...